NCT07425054 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07425054
Title	HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Jennifer Dorth
Indications	anal canal squamous cell carcinoma anal margin squamous cell carcinoma
Therapies	Fluorouracil + Mitomycin C Fluorouracil + Mitomycin C + Retifanlimab Capecitabine + Mitomycin C + Retifanlimab Capecitabine + Mitomycin C
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center		Cleveland	Ohio	44106	United States	Details
Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Center		Cleveland	Ohio	44195	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07425054Clinical Trial Detail